Human recombinant activated protein C for severe sepsis

Area of Science:

• Critical Care Medicine
• Pharmacology
• Clinical Trials

Background:

• Sepsis is a life-threatening condition requiring novel therapeutic strategies.
• Human recombinant activated protein C (APC) has been investigated as a potential treatment for severe sepsis.
• There is a need to evaluate the clinical effectiveness of APC in reducing sepsis-induced mortality.

Purpose of the Study:

• To assess the clinical effectiveness of activated protein C (APC) in treating patients with severe sepsis or septic shock.
• To determine if APC reduces mortality rates in adult and pediatric sepsis patients.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Searched multiple databases (Cochrane, MEDLINE, EMBASE, LILACS) without language restrictions.
• Included four RCTs with 4911 participants; analyzed 28-day mortality and bleeding risk using random-effects models.

Main Results:

• Activated protein C (APC) did not significantly reduce 28-day mortality in adult severe sepsis patients (RR 0.92, 95% CI 0.72-1.18).
• No clear association between APC effectiveness and sepsis severity (APACHE II score).
• APC use was associated with a statistically significant increase in bleeding risk (RR 1.48, 95% CI 1.07-2.06).

Conclusions:

• Activated protein C (APC) is not recommended for sepsis patients with an APACHE II score below 25 or for pediatric patients.
• Limited evidence supports APC use in high-risk severe sepsis patients; caution is advised.
• Further high-quality RCTs, preferably by non-profit organizations, are needed to clarify the role of APC in severe sepsis.